The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy

Irinotecan, a standard of care therapy for CRC, elicits cytotoxic effects by generating double strand breaks resulting in DNA damage. The activation of the ATM pathway plays a fundamental role in regulating the cellular response and repair to DNA damage. The objective of this preclinical study was t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Greene, Justin, Nguyen, Anna, Bagby, Stacey M., Jones, Gemma N., Tai, WM., Quackenbush, Kevin S., Schreiber, Anna, Messersmith, Wells A., Devaraj, Kalpana M., Blatchford, Patrick, Eckhardt, S. Gail, Cadogan, Elaine B., Hughes, Gareth D., Smith, Aaron, Pitts, Todd M., Arcaroli, John J.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5762293/
https://ncbi.nlm.nih.gov/pubmed/29340025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22920
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados